Bath & Body Works reported better-than-expected Q2 results and raised its FY26 EPS guidance. However, analysts responded by lowering their price targets, indicating underlying concerns about future performance despite the beat. This suggests a cautious outlook from the analyst community.
Bath & Body Works (BBWI) announced Q2 results that surpassed analyst expectations for both adjusted earnings and net sales, and also raised its fiscal 2026 GAAP and adjusted earnings forecasts. This would typically be a positive catalyst. However, the filing highlights that several prominent analysts (Morgan Stanley, Wells Fargo, UBS) subsequently lowered their price targets for BBWI. This indicates that while the immediate results were strong, analysts may be factoring in broader 'pressured underlying business trends' mentioned by the CEO, or other long-term concerns, leading to a more cautious outlook. The stock fell 2.9% on Thursday, suggesting the market is weighing the analyst sentiment more heavily than the earnings beat. For traders, this presents a short-term risk as analyst downgrades can create selling pressure, despite seemingly positive company news. The long-term implication depends on whether BBWI's 'Consumer First Formula' can truly overcome these underlying pressures.